Humanalbumin Octapharma

Humanalbumin Octapharma is a human serum albumin solution for injection, supplied in an unspecified strength, and marketed in the European Union. The product contains purified human serum albumin, a plasma protein that contributes to oncotic pressure. It is classified as a prescription‑only albumin (plasma protein) indicated for volume expansion and plasma volume replacement. Humanalbumin Octapharma is administered intravenously under medical supervision in clinical settings by qualified healthcare professionals.

Humanalbumin Octapharma is used when rapid restoration of intravascular volume is required or when low plasma albumin levels compromise oncotic pressure.

- Hypovolemia associated with trauma, hemorrhage, or dehydration. - Shock states, including septic or cardiogenic shock. - Severe burns with fluid loss. - Hypoalbuminemia due to liver disease, nephrotic syndrome, or malnutrition. - Volume expansion during cardiac or major abdominal surgery. - Plasma volume replacement in patients undergoing plasma exchange.

Adverse reactions to Humanalbumin Octapharma are generally related to the infusion process or to immune‑mediated responses, and they can range from mild, transient events to rare, severe complications.

Common: - Transient fever or chills. - Mild hypotension or hypertension during infusion. - Headache or dizziness. - Nausea or vomiting. - Localized erythema or swelling at the injection site. - Flushing or warmth sensation.

Serious: - Anaphylactic or severe allergic reactions. - Acute hemolysis. - Volume overload leading to pulmonary edema. - Thromboembolic events. - Transmission of infectious agents (theoretical risk). - Renal dysfunction or failure.

When using Humanalbumin Octapharma, clinicians should assess patient condition and monitor for potential complications, especially in vulnerable populations.

- Assess volume status and cardiac function before infusion. - Use caution in patients with renal or hepatic impairment. - Monitor vital signs and fluid balance during and after administration. - Avoid rapid infusion rates that may provoke hypotension. - Consider risk of volume overload in patients with heart failure or pulmonary disease. - Screen for known hypersensitivity to human albumin products. - Ensure product is stored and handled according to manufacturer guidelines.

Humanalbumin Octapharma may interact with other agents that affect fluid balance, coagulation, or immune response, requiring careful management.

Avoid: - Concomitant use of high‑dose diuretics that may exacerbate hypovolemia. - Simultaneous administration of other colloid solutions that could cause volume overload. - Products containing latex if the infusion set includes latex components.

Use with caution: - Vasopressor agents, as changes in intravascular volume may alter dosing requirements. - Anticoagulants, because altered plasma volume can affect coagulation monitoring. - Immunosuppressive drugs, due to potential modulation of immune response. - Blood products, to avoid additive volume shifts.